Mr. David W. Gryska is an Independent Director of Seattle Genetics, Inc., since March 2005. From October 2014 through December 2018, Mr. Gryska served as Executive Vice President and Chief Financial Officer of Incyte Corporationrationration, a publiclytraded biopharmaceutical company. From May 2012 to December 2012, Mr. Gryska served as Chief Operating Officer and from August 2012 to December 2012, interim Chief Executive Officer of Myrexis Inc., a publiclytraded biotechnology company. From December 2006 to October 2010, he served as Senior Vice President and Chief Financial Officer of Celgene Corporationrationration. From October 2004 to December 2006, he was a principal at Strategic Consulting Group, where he provided strategic consulting to earlystage biotechnology companies. Mr. Gryska served at Scios, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer from November 2000 to October 2004, and as Vice President of Finance and Chief Financial Officer from December 1998 to November 2000. Scios was acquired by Johnson Johnson in 2003. From 1993 to December 1998, he served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways Corporationrationration, a medical device company which was later acquired by Boston Scientific Corporationrationration. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst Young LLP, an accounting firm. During his eleven years at Ernst Young LLP, he focused on technology industries, with an emphasis on biotechnology and healthcare companies.
Gryska holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University. In addition to Seattle Genetics, Mr. Gryska serves on the board of PDL BioPharma, Inc. and Aerie Pharmaceuticals, Inc., both publiclytraded biotechnology companies. With his years of experience as Chief Financial Officer, at Incyte Corporationrationrationration, Celgene, Scios, and Cardiac Pathways.
What is David W. Gryska's net worth?
The estimated net worth of David W. Gryska is at least $9.21 million as of November 11th, 2022. Mr. Gryska owns 40,253 shares of Seagen stock worth more than $9,207,471 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Gryska may own. Learn More about David W. Gryska's net worth.
How do I contact David W. Gryska?
Has David W. Gryska been buying or selling shares of Seagen?
David W. Gryska has not been actively trading shares of Seagen over the course of the past ninety days. Most recently, David W. Gryska sold 7,500 shares of the business's stock in a transaction on Friday, November 11th. The shares were sold at an average price of $129.10, for a transaction totalling $968,250.00. Following the completion of the sale, the director now directly owns 40,253 shares of the company's stock, valued at $5,196,662.30. Learn More on David W. Gryska's trading history.
Who are Seagen's active insiders?
Are insiders buying or selling shares of Seagen?
In the last twelve months, insiders at the biotechnology company sold shares 28 times. They sold a total of 162,022 shares worth more than $33,110,171.31. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company.
Learn More about insider trades at Seagen. Information on this page was last updated on 11/10/2023.